Organon & Co. (OGN): Operating Cash Flow
$700.00M
Year ended 2025-12-31
$737.00M
Trailing 12 months to 2026-06-30
-6.6%
3-year compound annual growth
-21.1%
5-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $700.00M | -25.5% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $939.00M | +17.5% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $799.00M | -6.9% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $858.00M | -60.3% | 2025-11-10, From 2022-01-01 |
| 2021-12-31 | $2.16B | -5.4% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $2.28B | -24.4% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $3.02B | n/a | 2022-03-21, From 2019-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $700.00M | -25.5% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $1.13B | n/m |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $560.00M | +3.5% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $1.36B | -2.9% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $238.50M | -34.3% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.90B | -1.7% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.40B | -12.3% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $524.08M | n/m |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $827.99M | +44.5% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗